{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Mitomycines : Questions médicales les plus fréquentes",
"headline": "Mitomycines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Mitomycines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-24",
"dateModified": "2026-02-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Mitomycines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Indolequinones",
"url": "https://questionsmedicales.fr/mesh/D045563",
"about": {
"@type": "MedicalCondition",
"name": "Indolequinones",
"code": {
"@type": "MedicalCode",
"code": "D045563",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.473.412"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Mitomycine",
"alternateName": "Mitomycin",
"url": "https://questionsmedicales.fr/mesh/D016685",
"about": {
"@type": "MedicalCondition",
"name": "Mitomycine",
"code": {
"@type": "MedicalCode",
"code": "D016685",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.473.412.249.350"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Porfiromycine",
"alternateName": "Porfiromycin",
"url": "https://questionsmedicales.fr/mesh/D011160",
"about": {
"@type": "MedicalCondition",
"name": "Porfiromycine",
"code": {
"@type": "MedicalCode",
"code": "D011160",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.473.412.249.700"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Mitomycines",
"alternateName": "Mitomycins",
"code": {
"@type": "MedicalCode",
"code": "D008937",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Elise Champeil",
"url": "https://questionsmedicales.fr/author/Elise%20Champeil",
"affiliation": {
"@type": "Organization",
"name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA; The Graduate Center of the City University of New York, New York, NY 10016, USA. Electronic address: echampeil@jjay.cuny.edu."
}
},
{
"@type": "Person",
"name": "Owen Zacarias",
"url": "https://questionsmedicales.fr/author/Owen%20Zacarias",
"affiliation": {
"@type": "Organization",
"name": "Department of Sciences, John Jay College of Criminal Justice, New York, NY 10019, United States."
}
},
{
"@type": "Person",
"name": "Maggie Zheng",
"url": "https://questionsmedicales.fr/author/Maggie%20Zheng",
"affiliation": {
"@type": "Organization",
"name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: maggie.zheng@jjay.cuny.edu."
}
},
{
"@type": "Person",
"name": "Timothy Snyder",
"url": "https://questionsmedicales.fr/author/Timothy%20Snyder",
"affiliation": {
"@type": "Organization",
"name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: timothy.snyder@jjay.cuny.edu."
}
},
{
"@type": "Person",
"name": "Gloria Proni",
"url": "https://questionsmedicales.fr/author/Gloria%20Proni",
"affiliation": {
"@type": "Organization",
"name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: gproni@jjay.cuny.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Mitomycin Intravascular Chemoembolization for Corneal Neovascularization.",
"datePublished": "2024-08-23",
"url": "https://questionsmedicales.fr/article/39177412",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/ICO.0000000000003681"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mitomycin C as an Anti-Persister Strategy against",
"datePublished": "2024-08-28",
"url": "https://questionsmedicales.fr/article/39334989",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/antibiotics13090815"
}
},
{
"@type": "ScholarlyArticle",
"name": "Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer.",
"datePublished": "2023-09-18",
"url": "https://questionsmedicales.fr/article/37754536",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/curroncol30090621"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mitomycin C 0.2 mg/ml vs. Mitomycin C 0.4mg/ml during the implantation of an ab externo SIBS microshunt: A mega-analysis.",
"datePublished": "2024-06-06",
"url": "https://questionsmedicales.fr/article/38851392",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ogla.2024.06.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "Use of Mitomycin-C in Laryngotracheal Stenosis: A Focused Clinical Review.",
"datePublished": "2023-07-01",
"url": "https://questionsmedicales.fr/article/37271867",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/LBR.0000000000000933"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Indoles",
"item": "https://questionsmedicales.fr/mesh/D007211"
},
{
"@type": "ListItem",
"position": 6,
"name": "Indolequinones",
"item": "https://questionsmedicales.fr/mesh/D045563"
},
{
"@type": "ListItem",
"position": 7,
"name": "Mitomycines",
"item": "https://questionsmedicales.fr/mesh/D008937"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Mitomycines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Mitomycines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-04-29",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Mitomycines",
"description": "Comment diagnostiquer une tumeur sensible aux mitomycines ?\nQuels tests sont utilisés pour évaluer l'efficacité des mitomycines ?\nLes mitomycines sont-elles utilisées pour tous les types de cancer ?\nQuels signes cliniques indiquent un traitement par mitomycines ?\nComment évaluer la toxicité des mitomycines ?",
"url": "https://questionsmedicales.fr/mesh/D008937#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Mitomycines",
"description": "Quels sont les effets secondaires courants des mitomycines ?\nLes mitomycines provoquent-elles des douleurs ?\nComment les mitomycines affectent-elles le système immunitaire ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes mitomycines causent-elles des réactions allergiques ?",
"url": "https://questionsmedicales.fr/mesh/D008937#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Mitomycines",
"description": "Peut-on prévenir les effets secondaires des mitomycines ?\nY a-t-il des recommandations alimentaires pendant le traitement ?\nComment minimiser le risque d'infections pendant le traitement ?\nLes vaccinations sont-elles recommandées avant le traitement ?\nFaut-il éviter certains médicaments pendant le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D008937#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Mitomycines",
"description": "Comment les mitomycines sont-elles administrées ?\nLes mitomycines sont-elles combinées avec d'autres traitements ?\nQuelle est la durée typique d'un traitement par mitomycines ?\nQuelles précautions doivent être prises lors du traitement ?\nLes mitomycines nécessitent-elles une hospitalisation ?",
"url": "https://questionsmedicales.fr/mesh/D008937#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Mitomycines",
"description": "Quelles sont les complications possibles des mitomycines ?\nLes mitomycines peuvent-elles causer des cancers secondaires ?\nComment gérer une réaction allergique aux mitomycines ?\nLes mitomycines affectent-elles la fertilité ?\nQuels sont les signes d'une toxicité sévère ?",
"url": "https://questionsmedicales.fr/mesh/D008937#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Mitomycines",
"description": "Qui est à risque d'effets secondaires des mitomycines ?\nLes antécédents médicaux influencent-ils le traitement ?\nLe mode de vie affecte-t-il l'efficacité des mitomycines ?\nY a-t-il des facteurs génétiques à considérer ?\nLes interactions médicamenteuses augmentent-elles les risques ?",
"url": "https://questionsmedicales.fr/mesh/D008937#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une tumeur sensible aux mitomycines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur des examens d'imagerie et des biopsies pour évaluer la sensibilité."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité des mitomycines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de réponse tumorale et des marqueurs biologiques sont utilisés pour évaluer l'efficacité."
}
},
{
"@type": "Question",
"name": "Les mitomycines sont-elles utilisées pour tous les types de cancer ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles sont principalement utilisées pour certains cancers comme le cancer de la vessie et le sarcome."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent un traitement par mitomycines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme la progression tumorale ou la récidive peuvent indiquer un traitement par mitomycines."
}
},
{
"@type": "Question",
"name": "Comment évaluer la toxicité des mitomycines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La toxicité est évaluée par des analyses sanguines et l'observation des effets secondaires cliniques."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants des mitomycines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, vomissements, et suppression de la moelle osseuse."
}
},
{
"@type": "Question",
"name": "Les mitomycines provoquent-elles des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent provoquer des douleurs abdominales ou des douleurs liées à la tumeur traitée."
}
},
{
"@type": "Question",
"name": "Comment les mitomycines affectent-elles le système immunitaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent entraîner une immunosuppression, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à surveiller ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveillez des symptômes comme fatigue excessive, fièvre ou signes d'infection."
}
},
{
"@type": "Question",
"name": "Les mitomycines causent-elles des réactions allergiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réactions allergiques sont rares mais possibles, nécessitant une attention médicale."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les effets secondaires des mitomycines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments antiémétiques peuvent aider à prévenir les nausées et vomissements."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations alimentaires pendant le traitement ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et hydratation adéquate sont recommandées pour soutenir le traitement."
}
},
{
"@type": "Question",
"name": "Comment minimiser le risque d'infections pendant le traitement ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez les foules, lavez-vous les mains fréquemment et consultez un médecin en cas de fièvre."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles recommandées avant le traitement ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des vaccinations peuvent être recommandées pour réduire le risque d'infections."
}
},
{
"@type": "Question",
"name": "Faut-il éviter certains médicaments pendant le traitement ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent interagir avec les mitomycines, consultez votre médecin."
}
},
{
"@type": "Question",
"name": "Comment les mitomycines sont-elles administrées ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont généralement administrées par voie intraveineuse ou en perfusion."
}
},
{
"@type": "Question",
"name": "Les mitomycines sont-elles combinées avec d'autres traitements ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent combinées avec d'autres chimiothérapies ou radiothérapies."
}
},
{
"@type": "Question",
"name": "Quelle est la durée typique d'un traitement par mitomycines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée varie, mais un cycle de traitement dure généralement de 3 à 6 semaines."
}
},
{
"@type": "Question",
"name": "Quelles précautions doivent être prises lors du traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveillez les signes de toxicité et ajustez les doses si nécessaire sous supervision médicale."
}
},
{
"@type": "Question",
"name": "Les mitomycines nécessitent-elles une hospitalisation ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, mais une hospitalisation peut être nécessaire pour surveiller les effets secondaires."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des mitomycines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections, des saignements et des problèmes rénaux."
}
},
{
"@type": "Question",
"name": "Les mitomycines peuvent-elles causer des cancers secondaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'utilisation prolongée peut augmenter le risque de cancers secondaires."
}
},
{
"@type": "Question",
"name": "Comment gérer une réaction allergique aux mitomycines ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "En cas de réaction allergique, arrêtez le traitement et consultez immédiatement un médecin."
}
},
{
"@type": "Question",
"name": "Les mitomycines affectent-elles la fertilité ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent affecter la fertilité, il est conseillé de discuter des options de préservation."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'une toxicité sévère ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des saignements inhabituels, des douleurs abdominales sévères ou de la fièvre."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets secondaires des mitomycines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients âgés ou ceux avec des problèmes rénaux sont plus à risque d'effets secondaires."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le traitement ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies hématologiques ou rénales peuvent influencer le traitement."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il l'efficacité des mitomycines ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut améliorer la tolérance et l'efficacité du traitement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs génétiques à considérer ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines variations génétiques peuvent influencer la réponse aux mitomycines."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses augmentent-elles les risques ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines interactions peuvent augmenter les risques d'effets secondaires graves."
}
}
]
}
]
}
John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA; The Graduate Center of the City University of New York, New York, NY 10016, USA. Electronic address: echampeil@jjay.cuny.edu.
Departamento de Química Orgánica, Facultade de Química, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain. Electronic address: manuel.paz@usc.es.
John A. Moran Eye Center, University of Utah, Salt Lake City, USA; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada; Prism Eye Institute, Mississauga, Canada.
The purpose of the study was to evaluate the efficacy of mitomycin C intravascular chemoembolization (MICE) for corneal neovascularization (CNV)....
This is a prospective, nonrandomized, interventional study. Patients with stable CNV irrespective of the underlying etiology were enrolled in the study. 0.1% mitomycin C was injected intravascularly i...
Eight eyes from 8 patients with corneal neovascularization and lipid keratopathy were studied. The mean age at treatment was 37 ± 12.75 (range 17-64) years. The median follow-up was 419.5 days (74-116...
MICE effectively reduced neovascularization with no immediate safety concerns, though its impact on vision and long-term safety requires further investigation with larger, longer term studies....
The combination of several therapeutic strategies is often seen as a good way to decrease resistance rates, since bacteria can more easily overcome single-drug treatments than multi-drug ones. This st...
Since EXTRA, a non-randomized phase II trial with 31 patients, explored the use of capecitabine, mitomycin and radiation therapy (RT) in the treatment of localized squamous cell carcinoma of the anal ...
To compare the effectiveness and adverse event profile of standalone SIBS microshunt implantation with adjunct MMC 0.2 mg/ml and MMC 0.4 mg/ml....
Mega-analysis using individual patient data from international prospective and retrospective clinical studies....
Patients with glaucoma who underwent implantation of a SIBS microshunt with MMC as a standalone procedure....
A comparison of eyes that received MMC 0.2 mg/ml or 0.4 mg/ml MAIN OUTCOMES MEASURES: Primary outcome was complete success defined as the proportion of eyes at one year with all of the following: (1) ...
At 1 year, the complete success rate was significantly higher (71.3% vs 50.46%, p<0.001) and the median IOP significantly lower (13.0 vs. 14.2 mmHg, p<0.05) in the MMC 0.4 mg/ml group. MMC 0.2 mg/ml w...
SIBS microshunt implantation with MMC 0.4 mg/ml resulted in a higher success rate with greater IOP reduction compared to MMC 0.2 mg/ml. Higher MMC concentration was not associated with increased serio...
Therapeutic options for managing laryngotracheal stenosis (LTS) are limited. Endoscopy is a minimally invasive approach to treating LTS, but carries a high risk of stenosis recurrence. Mitomycin C (MM...
A focused literature search was carried out from PubMed on June 12, 2022 using the terms "mitomycin c AND stenosis" in all fields with no date limitations. Evidence-based recommendations relevant to t...
Twenty-nine studies were reviewed. The efficacy of MMC as an adjunct therapy for LTS varied across studies. Randomized controlled trials have not shown an outcome difference with MMC use, although met...
The role for MMC as an adjunct therapy in LTS is uncertain. While safe in its application, the efficacy of MMC in reducing stenosis recurrence remains a matter of debate. Large, prospective studies ar...
Toxic anterior segment (TASS) is a rare acute sterile anterior segment inflammation that typically develops within 12 to 24 hours after an anterior segment surgery. The purpose of this case report is ...
A 58-year-old male glaucoma patient was initially managed medically for primary open angle glaucoma with antiglaucoma medications. There was rapidly progressive glaucomatous optic nerve damage in his ...
The post-operative condition of the patient's eye was stormy with diffuse limbus-to-limbus corneal edema and profound Descemet's membrane folds, among other features of TASS, with associated deteriora...
Although there is no documented report of TASS following trabeculectomy with mitomycin C, surgeons should be alerted to this possibility. Preventive measures include extreme care to avoid errors while...
To review the literature on the adjuvant use of mitomycin C (MMC) during dacryocystorhinostomy (DCR) in adults with primary nasolacrimal duct obstructions (NLDOs) to determine the efficacy in improvin...
A literature search conducted in November 2020 and updated in November 2022 yielded 137 articles. Twenty-four articles met the inclusion criteria and were rated for level of evidence by the panel meth...
Six of the 24 articles were rated level I evidence, 15 level II , and 3 level III. In primary external DCR, MMC significantly improved functional outcomes in 3 of 9 series. In primary endoscopic endon...
Intraoperative use of MMC in external and endoscopic endonasal DCR has been shown to improve functional and anatomic outcomes compared with controls in some series, but there is no agreement on the re...
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article....
Mitomycin C (MMC) repair factor A (mrfA) and factor B (mrfB), encode a conserved helicase and exonuclease that repair DNA damage in the soil-dwelling bacterium Bacillus subtilis. Here we have focused ...
Background Trabeculectomy, with the application of mitomycin C (MMC), has been the gold standard glaucoma-filtering surgery. The conventional method of applying MMC using soaked sponges does not ensur...